Abstract
Immune dependent growth and development of infectious agents and pathogenesis are increasingly being recognized as crucial for designing efficient immunotherapeutic approaches for Mycobacterium tuberculosis. Nitric oxide (NO) in the context of mycobacterial infection is an essential component of the protective armory of host innate immune system. However, the ability of NO to suppress host immune response questions the traditional view that production of NO is actually designed for anti-microbial mechanism. Human tuberculosis is considered as a prime example of a disease controlled dominantly by cell-mediated and not by humoral immunity. Interleukins like IL-12 and IL-8 play important roles in anti-tuberculosis immunity. While IL-8 has a central role in leukocyte recruitment to areas of granuloma formation, IL-12 helps in the generation of effective cell-mediated immune response in tuberculosis. NO shows an ability to inhibit mycobacterial infection by inducing innate-cytotoxic response and by increasing IL-8 induction. However, it may become a problem in later phase when it converts a protective Th1 response to a subversive Th2 response mainly by inhibiting IL-12 cytokine, thus acting as a potential regulator of Th1/Th2 response. This review intends to explore the possibilities that can be envisioned for exploring NO from immunotherapeutic perspectives in mycobacterial immunity.
Keywords: Mycobacterium tuberculosis, macrophage, nitric oxide, interleukin-12, Th1/Th2, immunoregulation
Current Signal Transduction Therapy
Title: Nitric Oxide: Friendly Rivalry in Tuberculosis
Volume: 2 Issue: 2
Author(s): Sangita Mukhopadhyay, Shiny Nair and Seyed E. Hasnain
Affiliation:
Keywords: Mycobacterium tuberculosis, macrophage, nitric oxide, interleukin-12, Th1/Th2, immunoregulation
Abstract: Immune dependent growth and development of infectious agents and pathogenesis are increasingly being recognized as crucial for designing efficient immunotherapeutic approaches for Mycobacterium tuberculosis. Nitric oxide (NO) in the context of mycobacterial infection is an essential component of the protective armory of host innate immune system. However, the ability of NO to suppress host immune response questions the traditional view that production of NO is actually designed for anti-microbial mechanism. Human tuberculosis is considered as a prime example of a disease controlled dominantly by cell-mediated and not by humoral immunity. Interleukins like IL-12 and IL-8 play important roles in anti-tuberculosis immunity. While IL-8 has a central role in leukocyte recruitment to areas of granuloma formation, IL-12 helps in the generation of effective cell-mediated immune response in tuberculosis. NO shows an ability to inhibit mycobacterial infection by inducing innate-cytotoxic response and by increasing IL-8 induction. However, it may become a problem in later phase when it converts a protective Th1 response to a subversive Th2 response mainly by inhibiting IL-12 cytokine, thus acting as a potential regulator of Th1/Th2 response. This review intends to explore the possibilities that can be envisioned for exploring NO from immunotherapeutic perspectives in mycobacterial immunity.
Export Options
About this article
Cite this article as:
Mukhopadhyay Sangita, Nair Shiny and Hasnain E. Seyed, Nitric Oxide: Friendly Rivalry in Tuberculosis, Current Signal Transduction Therapy 2007; 2 (2) . https://dx.doi.org/10.2174/157436207780619536
DOI https://dx.doi.org/10.2174/157436207780619536 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Approaches to Drug Discovery for Chagas Disease: Methodological Advances
Combinatorial Chemistry & High Throughput Screening State of the Art of Nanobiotechnology Applications in Neglected Diseases
Current Nanoscience Late and Low Compliance with Hepatitis B Serology Screening Among HIV-Infected Patients in a Resource-Limited Setting: An Issue to Improve HIV Care
Current HIV Research Antimicrobial Evaluation of 5-Substituted Aryl 1H-Tetrazoles
Medicinal Chemistry Design, Synthesis and Docking Study of Some Novel Isatin- Quinoline Hybrids as Potential Antitubercular Agents
Anti-Infective Agents Repurposing Non-Antimicrobial Drugs and Clinical Molecules to Treat Bacterial Infections
Current Pharmaceutical Design Editorial
Current Molecular Medicine Treatment Options in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders
Current Pharmaceutical Design Design, Synthesis, SAR Study, Antimicrobial and Anticancer Evaluation of Novel 2-Mercaptobenzimidazole Azomethine Derivatives
Mini-Reviews in Medicinal Chemistry Design and Development of ChemInfoCloud: An Integrated Cloud Enabled Platform for Virtual Screening
Combinatorial Chemistry & High Throughput Screening Formulation and Evaluation of Rifampicin Liposomes for Buccal Drug Delivery
Current Drug Delivery Applications and Case Studies of the Next-Generation Sequencing Technologies in Food, Nutrition and Agriculture
Recent Patents on Food, Nutrition & Agriculture Detection of the Incidence of Infections and Acute Biochemical Changes in Diffused Large B-Cell Lymphoma Patients Treated with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) with and without Rituximab
Current Drug Safety Editorial (Thematic Issue: New Antimicrobial Therapeutics)
Current Medicinal Chemistry Update on Clinical, Pathophysiological and Therapeutic Aspects in ANCAAssociated Vasculitides
Current Drug Discovery Technologies Nicotinamide Adenine Dinucleotide Based Therapeutics
Current Medicinal Chemistry Adenosine and Adenosine Receptors in the Pathomechanism and Treatment of Respiratory Diseases
Current Medicinal Chemistry Novel Synthetic Compounds as Potential Anticryptococcal Agents
Current Organic Synthesis Hodgkin Lymphoma in HIV Positive Patients
Current HIV Research Contribution of Antimicrobial Peptides to the Development of New and Efficient Antimicrobial Strategies
Current Proteomics